Kings Path Partners LLC Makes New Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Kings Path Partners LLC purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 21,425 shares of the biotechnology company's stock, valued at approximately $425,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. California State Teachers Retirement System increased its position in shares of ADMA Biologics by 4.2% during the fourth quarter. California State Teachers Retirement System now owns 217,391 shares of the biotechnology company's stock worth $3,728,000 after purchasing an additional 8,717 shares in the last quarter. Heck Capital Advisors LLC acquired a new stake in ADMA Biologics during the 4th quarter worth about $225,000. Mackenzie Financial Corp boosted its holdings in ADMA Biologics by 212.2% in the fourth quarter. Mackenzie Financial Corp now owns 74,539 shares of the biotechnology company's stock valued at $1,278,000 after purchasing an additional 50,660 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in ADMA Biologics during the 4th quarter worth about $85,000. Finally, Neo Ivy Capital Management boosted its stake in shares of ADMA Biologics by 512.6% during the 4th quarter. Neo Ivy Capital Management now owns 297,627 shares of the biotechnology company's stock worth $5,104,000 after acquiring an additional 249,043 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Insider Buying and Selling

In other news, Director Lawrence P. Guiheen sold 7,779 shares of ADMA Biologics stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total transaction of $158,069.28. Following the sale, the director now directly owns 114,830 shares in the company, valued at approximately $2,333,345.60. The trade was a 6.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.50% of the company's stock.

ADMA Biologics Stock Performance

NASDAQ ADMA traded up $0.10 on Tuesday, hitting $20.53. 603,347 shares of the company's stock were exchanged, compared to its average volume of 3,682,243. ADMA Biologics, Inc. has a fifty-two week low of $9.63 and a fifty-two week high of $25.67. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm's 50-day moving average price is $20.66 and its two-hundred day moving average price is $18.85. The firm has a market cap of $4.90 billion, a price-to-earnings ratio of 73.32 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same quarter in the previous year, the business posted $0.08 EPS. ADMA Biologics's revenue for the quarter was up 40.2% compared to the same quarter last year. On average, research analysts expect that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ADMA shares. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th. Raymond James raised their target price on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $24.25.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.